Fifth Third Bancorp
APGE

Fifth Third Bancorp’s Apogee Therapeutics APGE Stock Holding History

Fifth Third Bancorp’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44M Sell
25,914
-37,886
-59% -$3.41M 0.01% 989
2026
Q1 		$5.37M Buy
+63,800
New +$4.63M 0.01% 695

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fifth Third Bancorp's APGE Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Apogee Therapeutics (APGE) stake by 59% in Q2 2026, selling an estimated $3.41M and leaving 25,914 shares worth $3.44M. The position accounts for 0.01% of the portfolio, ranked #989.

Fifth Third Bancorp first reported a position in APGE in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.37M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Fifth Third Bancorp held 25,914 shares of Apogee Therapeutics worth $3.44M as of Q2 2026.
  • Fifth Third Bancorp sold 37,886 Apogee Therapeutics shares in Q2 2026, an estimated $3.41M.
  • Apogee Therapeutics made up 0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #989 holding.
  • Fifth Third Bancorp first reported a position in Apogee Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Fifth Third Bancorp's Apogee Therapeutics position peaked at $5.37M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.